Drug Research
iBio Enters into Agreement with Safi Biosolutions to Develop Growth Factors and Cytokines Using the FastPharming System
iBio, Inc., a biotech innovator and biologics contract manufacturing organization, announced that it has entered into a Master Services Agreement (“MSA”) with Boston-based Safi...
Drug Research
Eisai enters joint research pact with four research organizations in Japan for development of therapeutics for novel COVID-19
Eisai Co Ltd announced that it has entered into a joint research agreement with four research organizations (KAN Research Institute, National Center for Global...
Drug Research
Syngene joins global industry consortium to accelerate collaborative research in COVID-19 testing
Syngene International Limited announced that it has joined a global consortium of 19 organizations from the healthcare industry, led by Bristol Myers Squibb, to...
Drug Research
Regenerons REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized COVID-19 Patients
Regeneron Pharmaceuticals, Inc. announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cocktail REGN-COV2 showing...
Drug Research
Major Pharma Companies, Including Novartis And Merck, Build Federated Learning Platform For Drug Discovery
Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Institut De Recherches Servier, Janssen, Merck, and Novartis — inked an agreement to build a shared platform...
Drug Research
Alnylam Pharmaceuticals partners with Sharp on packaging RNA interference (RNAi) therapeutics for Europe
Alnylam Pharmaceuticals Inc., the leading RNA interference (RNAi) therapeutics company, and Sharp, part of UDG Healthcare, announced an agreement for the packaging of Alnylam’s...
Drug Research
Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations
Seattle Genetics, Inc. and Merck, known as MSD outside the United States and Canada, announced two new strategic oncology collaborations.
The companies will globally develop...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read